FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885462375> ?p ?o ?g. }

• W2885462375 abstract "Background Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the EU and Japan. Objectives To report results from a 24 week (wk) global, Phase 2, double-blind, placebo (PBO)-controlled study of Bari in patients with SLE receiving standard therapy. Methods Patients with SLE (positive ANA or anti-dsDNA, clinical SLEDAI-2K≥4, arthritis or rash required) receiving stable background SLE therapy were randomised 1:1:1 to PBO, or Bari (2- or 4 mg) once daily. The primary endpoint was resolution of SLEDAI-2K arthritis or rash at wk 24. Results Of 314 patients randomised, 79%, 82%, and 83% completed 24 wks of treatment in PBO, Bari 2 mg, and Bari 4 mg groups, respectively. At wk 24, a significantly greater proportion of patients in Bari 4 mg group compared to PBO achieved resolution of SLEDAI-2K arthritis or rash (67% vs 53%, p Data are n (%) patients, unless otherwise indicated. D=least squares mean change from baseline. ‡Includes up to 30 days post treatment. CLASI=Cutaneous Lupus Erythematosus Disease Area and Severity Index; n=number of patients in the analysis population; n=number of patients in the specified category; TEAE=treatment emergent adverse event.*p≤0.05. Conclusions In patients with SLE receiving standard background therapy, once-daily oral Bari 4 mg was associated with significant clinical improvements compared to PBO and an acceptable benefit/risk profile. These findings support further study of Bari 4 mg as a potential therapy for patients with SLE. Disclosure of Interest D. Wallace Consultant for: Eli Lilly and Company, EMD Merck Serono, Pfizer, GSK, R. Furie Consultant for: Eli Lilly and Company, Y. Tanaka Grant/research support from: Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa- Kirin, Eisai, Ono, Speakers bureau: Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, UCB, K. Kalunian Consultant for: Eli Lilly and Company, M. Mosca: None declared, M. Petri Consultant for: Eli Lilly and Company, T. Dorner Grant/research support from: Roche/Chugai, Janssen, Sanofi, Consultant for: AbbVie, Celgene, Eli Lilly, Roche, UCB, MSD, Pfizer/Hospira, Novartis, Speakers bureau: Amgen, Celgene, Biogen, M. Cardiel Grant/research support from: Pfizer, Gilead, Roche, Janssen, Consultant for: Eli Lilly and Company, Pfizer, Speakers bureau: Eli Lilly and Company, Pfizer, Abbvie, I. Bruce Grant/research support from: Genzyme, GSK, Consultant for: BMS, Eli Lilly and Company, GSK, Astra Zeneca, Speakers bureau: GSK, E. Gomez Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, T. Carmack Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, J. Janes Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Linnik Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Silk Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, R. Hoffman Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company" @default.
• W2885462375 created "2018-08-22" @default.
• W2885462375 creator A5006272183 @default.
• W2885462375 creator A5013612547 @default.
• W2885462375 creator A5013851404 @default.
• W2885462375 creator A5013861508 @default.
• W2885462375 creator A5015953107 @default.
• W2885462375 creator A5029315017 @default.
• W2885462375 creator A5040817195 @default.
• W2885462375 creator A5047950724 @default.
• W2885462375 creator A5071079442 @default.
• W2885462375 creator A5071430304 @default.
• W2885462375 creator A5076651506 @default.
• W2885462375 creator A5079090212 @default.
• W2885462375 creator A5082713013 @default.
• W2885462375 creator A5086942556 @default.
• W2885462375 creator A5087581059 @default.
• W2885462375 date "2018-06-01" @default.
• W2885462375 modified "2023-10-18" @default.
• W2885462375 title "OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study" @default.
• W2885462375 doi "https://doi.org/10.1136/annrheumdis-2018-eular.1918" @default.
• W2885462375 hasPublicationYear "2018" @default.
• W2885462375 type Work @default.
• W2885462375 sameAs 2885462375 @default.
• W2885462375 citedByCount "2" @default.
• W2885462375 countsByYear W28854623752019 @default.
• W2885462375 countsByYear W28854623752021 @default.
• W2885462375 crossrefType "proceedings-article" @default.
• W2885462375 hasAuthorship W2885462375A5006272183 @default.
• W2885462375 hasAuthorship W2885462375A5013612547 @default.
• W2885462375 hasAuthorship W2885462375A5013851404 @default.
• W2885462375 hasAuthorship W2885462375A5013861508 @default.
• W2885462375 hasAuthorship W2885462375A5015953107 @default.
• W2885462375 hasAuthorship W2885462375A5029315017 @default.
• W2885462375 hasAuthorship W2885462375A5040817195 @default.
• W2885462375 hasAuthorship W2885462375A5047950724 @default.
• W2885462375 hasAuthorship W2885462375A5071079442 @default.
• W2885462375 hasAuthorship W2885462375A5071430304 @default.
• W2885462375 hasAuthorship W2885462375A5076651506 @default.
• W2885462375 hasAuthorship W2885462375A5079090212 @default.
• W2885462375 hasAuthorship W2885462375A5082713013 @default.
• W2885462375 hasAuthorship W2885462375A5086942556 @default.
• W2885462375 hasAuthorship W2885462375A5087581059 @default.
• W2885462375 hasBestOaLocation W28854623751 @default.
• W2885462375 hasConcept C126322002 @default.
• W2885462375 hasConcept C142724271 @default.
• W2885462375 hasConcept C159654299 @default.
• W2885462375 hasConcept C197934379 @default.
• W2885462375 hasConcept C203014093 @default.
• W2885462375 hasConcept C203092338 @default.
• W2885462375 hasConcept C204787440 @default.
• W2885462375 hasConcept C27081682 @default.
• W2885462375 hasConcept C2775915377 @default.
• W2885462375 hasConcept C2776912625 @default.
• W2885462375 hasConcept C2777077863 @default.
• W2885462375 hasConcept C2778570526 @default.
• W2885462375 hasConcept C2779134260 @default.
• W2885462375 hasConcept C2908647359 @default.
• W2885462375 hasConcept C535046627 @default.
• W2885462375 hasConcept C71924100 @default.
• W2885462375 hasConcept C90924648 @default.
• W2885462375 hasConcept C99454951 @default.
• W2885462375 hasConceptScore W2885462375C126322002 @default.
• W2885462375 hasConceptScore W2885462375C142724271 @default.
• W2885462375 hasConceptScore W2885462375C159654299 @default.
• W2885462375 hasConceptScore W2885462375C197934379 @default.
• W2885462375 hasConceptScore W2885462375C203014093 @default.
• W2885462375 hasConceptScore W2885462375C203092338 @default.
• W2885462375 hasConceptScore W2885462375C204787440 @default.
• W2885462375 hasConceptScore W2885462375C27081682 @default.
• W2885462375 hasConceptScore W2885462375C2775915377 @default.
• W2885462375 hasConceptScore W2885462375C2776912625 @default.
• W2885462375 hasConceptScore W2885462375C2777077863 @default.
• W2885462375 hasConceptScore W2885462375C2778570526 @default.
• W2885462375 hasConceptScore W2885462375C2779134260 @default.
• W2885462375 hasConceptScore W2885462375C2908647359 @default.
• W2885462375 hasConceptScore W2885462375C535046627 @default.
• W2885462375 hasConceptScore W2885462375C71924100 @default.
• W2885462375 hasConceptScore W2885462375C90924648 @default.
• W2885462375 hasConceptScore W2885462375C99454951 @default.
• W2885462375 hasLocation W28854623751 @default.
• W2885462375 hasOpenAccess W2885462375 @default.
• W2885462375 hasPrimaryLocation W28854623751 @default.
• W2885462375 hasRelatedWork W2029338556 @default.
• W2885462375 hasRelatedWork W2138819917 @default.
• W2885462375 hasRelatedWork W2468589341 @default.
• W2885462375 hasRelatedWork W2913074078 @default.
• W2885462375 hasRelatedWork W2917268196 @default.
• W2885462375 hasRelatedWork W2944978304 @default.
• W2885462375 hasRelatedWork W3090550029 @default.
• W2885462375 hasRelatedWork W3118611254 @default.
• W2885462375 hasRelatedWork W4233016836 @default.
• W2885462375 hasRelatedWork W2738598104 @default.
• W2885462375 isParatext "false" @default.
• W2885462375 isRetracted "false" @default.
• W2885462375 magId "2885462375" @default.
• W2885462375 workType "article" @default.